The 2.4 mg dose, which became the standard dose carried forward into phase 3 trials, produced approximately 8% to 9% weight loss in 26 weeks
Together they produce a stronger, more sustained GH release than either compound alone, without the cortisol and prolactin spikes associated with older compounds like GHRP-2 or GHRP-6
Weeks 13 through 28: Weight loss continues but the rate gradually slows as the body adjusts
l-Carnitine has also demonstrated the potential to moderate lactate levels and promote oxygenation of heart tissue
For a deeper primer on the blends identity and rationale, see our explainer on what the KLOW peptide blend is, and for the outcomes literature see KLOW benefits: what research shows
At LaserAway, we recognize the challenges faced by Ideal Image patients who are unable to continue their care due to recent closures